HOME >> BIOLOGY >> NEWS
WSU scientist part of study seeking vaccines to combat potential bioterrorist attack

A research scientist at Wright State University is involved in a $1 million federal grant to combat a terrorist attack involving biological weapons.

Dawn Wooley, Ph.D., an associate professor in anatomy and physiology, is part of the Midwest Center of Excellence for Biodefense and Emerging Infectious Diseases Research.

"Our goal is to develop the diagnostic tools, therapeutics and vaccines that can be used to combat lethal agents or viruses and other infectious diseases identified by the Centers for Disease Control. We are particularly interested in agents that can be spread through the air," explained Wooley, who holds a doctorate from Harvard Medical School in virology, which is the study of viruses and viral diseases.

She became interested in this project after the terrorist attacks on Sept. 11, 2001, and subsequent anthrax scare. "My principal research work involves AIDS, but the threat involving bioterrorism is so great that I could not resist getting involved. This is so important to the United States and the world because some of these agents can kill people within a few days. Just think back to what the anthrax scare did to the postal service and you can realize how frightening a situation this can be."

The Midwest Center is a group of eight universities, including Wright State, which received funding from the National Institutes of Health. The University of Minnesota is the principal investigator and The Ohio State University is the co-principal investigator. The WSU research scientist is working with colleagues at both universities in her phase of the two-year project.

Wooley, who received initial funding for this project from Wright State, said the other participating institutions are the University of Cincinnati; University of Michigan; Indiana University; University of Illinois, Chicago; and Northwestern University.

The planning grant funds from NIH are related to a recently announced award of $350 mil
'"/>

Contact: Dawn Wooley
dawn.wooley@wright.edu
937-775-4993
Wright State University
15-Oct-2003


Page: 1 2

Related biology news :

1. EMBO Gold Medal 2004 goes to Spanish scientist
2. DNA lends scientists a hand, revealing new chemical reactions
3. UCSF scientist Joe Derisi named MaCarthur Fellow
4. Conference at UH opens doors for new scientists, engineers
5. Wisconsin scientists develop quick botox test
6. UCI scientists successfully target key HIV protein; breakthrough may lead to new drug therapies
7. Alaska scientists find Arctic tundra yields surprising carbon loss
8. DuPont scientist named one of the worlds top young innovators by MITs Technology Review Magazine
9. UAF scientists discover new marine habitat in Alaska
10. Information system to help scientists analyze mechanisms of social behavior
11. White House to honor UNC School of Medicine scientist for early career achievement

Post Your Comments:
(Date:5/5/2015)... 5, 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, reminds investors and media that ... is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series ... is themed Global Fraud: Where is the Trust in ...
(Date:4/27/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces that its Wocket® Smart ... week of May, 2015 and will be fulfilling all ... Gino Pereira , Chief Executive Officer said, ... Wocket® enters the consumer market. We would like to ...
(Date:4/21/2015)... 2015 High crime rate, ... boosting access control systems market in Saudi ... recently published report by TechSci Research " Saudi Arabia Access ... control systems market in Saudi Arabia ... access control systems market in the Kingdom is growing ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3
(Date:5/21/2015)... , May 21, 2015  Prima Biomed Ltd. ... that is striving to become a leader in the ... recently announced that the final CVac data from the ... a clear trend for a clinically meaningful improvement in ... second remission patients. In the group of ...
(Date:5/21/2015)... 21, 2015 Imagine being able ... and those of others. Being able to read faces ... read people to anticipate their thoughts and actions like ... and feelings to create unique abstract paintings and video, ... Get inside a first-person-shooter as it creates action, dialog, ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: RP) ... focused on the development of autologous cell therapies, ... International Society for Cellular Therapy (ISCT) on RepliCel,s ... in a Phase 1/2 clinical trial.  The presentation, ... 5:30 PM to 7:00 PM local time, will ...
Breaking Biology Technology:Correction Continues after Big Move - BrokerBank Securities, Inc. 25 Days to Meet ARGUS - The World's First Contactless Emotions Scanner 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3
Cached News: